PROFESSOR

Postdoctoral Training

1987-1990     Research Fellow, Department of Pathology, Dana-Farber
                      Cancer Institute and Harvard Medical School.

Academic Appointments

1990 – 1995         Instructor in Pathology, Dana Farber Cancer Institute and
                             Harvard Medical School
1996 – 2000         Assistant Professor of Medicine, Harvard Medical School
                             and Dana-Farber Cancer Institute
2000 – 2007         Associate Professor of Pathology, Tulane Health Sciences
                             Center, Tulane Cancer Center
2008 – Present     Professor of Pathology, Tulane Health Sciences Center
2008 – Present     Program leader of Cancer Genetics Program,Tulane Cancer Center
2009 – Present     Zimmerman Endowed Professor of Cancer Research, Tulane Cancer Center.

Grant Review Panels

US ARMY Prostate cancer Award Program (2003 and 2005)
National Institutes of Health – Experimental Virology Study Section (2003)
National Institutes of Health – AIDS-associated Opportunistic Infections & Cancer Study Section (2003-2005)
National Institutes of Health – AARR-A Study Section (2005)
National Institutes of Health – AIDS-associated Opportunistic Infections & Cancer Study Section (2006-2009)
National Institutes of Health – ZRG1 AARR-C (2009)
National Institutes of Health – ZRG1 IDM-C (2009)
National Institutes of Health – ZRG1 AARR-K (April 2010)
National Institutes of Health – EDRN Biomarker Development Labs (U01) (May 2010)
National Institutes of Health – ZCA1 RPRB Basic and translational Molecular Oncology (P01) (January, 2011)
National Institutes of Health – AIDS-associated Opportunistic Infections & Cancer Study Section (July, 2011)
National Institutes of Health – AIDS-associated Opportunistic Infections & Cancer Study Section (March, 2012)
National Institutes of Health – ZCA1 RPRB-J (01) R NCI Program Project Study Section (June, 2012)
National Institutes of Health – ZRG1 AARR-K(03) AOIC conflicts review (July, 2012)
National Institutes of Health – NCI P01 SEP review meeting (October, 2012)

Editorial Boards

1993 – 2002  Editor, Analytical Biochemistry.

Journal Review Assignments

J Virol, Virol, Oncogene, PloS Pathogens, Journal of Biological Chemistry, Trends in Microbiology, Journal of Molecular Biology, Journal of Clinical Microbiology, J. General Virology.

Other Assignments

AIDS and Cancer Specimen Resource (ACSR) review panel.

U. S. Patents  

1) Approved:  US 5759803 – Retinoblastoma-Associated Protein 1 (E2F-1) Polypeptides and cDNA.
 

Selected Publications:

1. Lin, Z, Puetter A, Coco J, Xu G, Strong, MJ, Wang, X, Fewell, C, Baddoo, M, Taylor CM, Flemington, EK. Detection of Murine Leukemia Virus in the Epstein-Barr Virus-Positive Human B-Cell Line JY, Using a Computational RNA-Seq-Based Exogenous Agent Detection Pipeline, PARSES. J Virol. 2012 Mar;86(6):2970-7. PMID:22238296.

2. Concha, M, Wang, X, Cao, S, Baddoo, M, Fewell, C, Lin, Z, Hulme, W, Hedges, D, McBride, J, Flemington, EK. Identification of new viral genes and transcript isoforms during Epstein-Barr virus reactivation using RNA-seq. J Virol. 2012 86:1458 (PMID: 22090128).

3. Lin, Z, and Flemington, EK. miRNAs in the pathogenesis of oncogenic human viruses. Cancer Letters, 2011; 305: 186-199 (PMID: 20943311)

4. Deng, N, Puetter, A, Zhang, K, Johnson, K Zhao, Z Taylor, CM, *Flemington, EK, *Zhu, D. Isoform-level microRNA-155 target prediction using RNA-seq. Nucl. Acids Res. 2011; 39:e61 (PMID: 21317189) (*corresponding authors)

5. Xu, G, Deng, N, Zhao, Z, Zhang, K, Judeh, T, Flemington, EK, Zhu, D. SAMMate: a GUI tool for processing short read alignments in SAM/BAM format. Source Code for Biology and Medicine. 2011; 6:2 (PMID: 21232146)

6. Lin, Z, Wang, X, Fewell, C, Cameron, J, Yin, Q, Flemington, EK. Differential expression of the miR-200 family microRNAs in epithelial and B-cells and regulation of Epstein-Barr virus reactivation by the miR-200 family member, miR-429.  J. Virol. 2010; 84:7892-7897 (PMID: 20484493).

7. Lin, Z, Xu, G, Deng, N, Taylor, CM, Zhu, D, Flemington, EK. Quantitative and qualitative RNA-seq based evaluation of Epstein-Barr virus transcription in type I latency Burkitt’s lymphoma cells. J Virol 2010; 84:13053-13058 (PMID: 20943983).

8. Yin, Q, Wang, X, Fewell, C, Cameron, J, Zhu, H, Baddoo, M, Lin, Z, Flemington, EK. MiR-155 inhibits Bone Morphogenetic Protein (BMP) signaling and BMP mediated Epstein Barr virus reactivation. J Virol 2010; 84:6318-6327 (PMID: 20427544).

9. Xu, G, Fewell, C, Taylor, CM, Deng, N, Hedges, D, Wang, X, Zhang, K, Lacey, M, Zhang, H, Yin, Q, Cameron, J, Lin, Z, Zhu, D, Flemington, EK. Transcriptome and targetome analysis in miR-155 expressing cells using RNA-seq. RNA 2010; 16:1610-1622 (PMID: 20584899).

10. Molina-Privado I, Rodríguez-Martínez M, Rebollo P, Martín-Pérez D, Artiga MJ, Menárguez J, Flemington EK, Piris MA, Campanero MR. E2F1 expression is deregulated and plays an oncogenic role in sporadic Burkitt's lymphoma. Cancer Res. 2009; 69:4052-4058.

11. Alvaro-Blanco, J, Martinez-Gac, L, Calonge, E, Rodriguez-Martinez, M, Molina-Privado, I, Redondo, JM, Alcami, J, Flemington, EK, Campanero, MR. A novel factor distinct from E2F mediates c-Myc promoter activation through its E2F element during exit from quiensence. Carcinogenesis 2009; 30:440-448.

12. Cameron, JE, Fewell, C, Yin, Q, McBride, J, Wang, X, Lin, Z, Flemington, EK. Differential expression of cellular microRNAs in EBV infected cells expressing type III vs type I latency genes. Virology 2008; 105:257-266.

13. Lin, Z, Fewell, C, Baddoo, M, McBride, J, and Flemington, EK. Complex regulation of EBV Zta ubiquitination. J Virol 2008; In Revision.

14. Oskowitz, AZ, Lu, J, Penfornis, P, Ylostalo, J, McBride, J, Flemington, EK, Prockop, D, and Pochampally, R. Human Multipotent Stromal Cells from Bone Marrow (hMSCs) and microRNA (miRNA): Regulation of Differentiation and Leukemia Inhibitory Factor Expression. PNAS 2008; 105:18372-18377.

15. Yin, Z, McBride, J, Fewell, C, Lacey, M, Wang, X, Lin, Z, Cameron, J, and Flemington, EK. microRNA-155 is an Epstein Barr virus induced gene that modulates Epstein Barr virus regulated gene expression pathways. J Virol. 2008; 82:5295-5306.

16. Yin, Z, Wang, X, McBride, J, Fewell, C, and Flemington, EK. B-cell receptor activation induces BIC/miR-155 expression through a conserved AP-1 element. J Biol. Chem. 2008; 283: 2654-2662.

17. Cameron, JE, Yin, Q, Fewell, C, Lacey, M, McBride, J, Wang, X, Lin, Z, Schaefer, BC, and Flemington, EK. The Epstein-Barr virus latent membrane protein 1 (LMP1) induces cellular microRNA-146a, a modulator of lymphocyte signaling pathways. J Virol. 2008; 82: 1946-1958.

Book Chapters:

Flemington, EK, and Rodriguez, A. Use of Gene Overexpression to assess Function in Cell Cycle Control. In Cell Cycle Checkpoint Control Protocols. (Ed. Lieberman, H) Methods in Molecular Biology 2004; 241:195-206.

Lin, Z, and Flemington, EK. Regulation of EBV latency by viral lytic proteins. In Epstein-Barr Virus Latency and Transformation. (Ed. Erle S. Robertson) Horizon Press: In press

 

Research Support:

As Principle Investigator

“Analysis of EBV type III latency on cellular miRNA gene expression”
Principal Investigator: Erik K Flemington
Type: R01
Agency: NIH [R01CA130752]
Period: April 1, 2008 to March 31, 2013

“Role of the cellular microRNA, miR-155, in EBV type III signaling”
Principal Investigator: Erik K Flemington
Type: R01
Agency: NIH [R01CA138268]
Period: July 1, 2009 – June 31, 2014

“Intercellular communication in Epstein Barr virus reactivation”
Principal Investigator: Erik K Flemington
Type: R01
Agency: NIH [R01AI101046]
Period: April 1, 2012 to March 31, 2017

COBRE

“Mentoring a Program in Cancer Genetics"
Program Director:
Dr. Flemington is the Core Director and Mentor of administrative core for this grant.
Type: COBRE
Agency: NIH (P20 RR020152)
Period: August 1st, 2004 to July 31st 2014

As Collaborator

“Supramolecular Approaches to Protein Inhibitors Activated by MicroRNA-21”
Principal Investigator: Janarthanan Jayawickramarajah
Type: R01
Agency: NIH (R01 GM09757)
Period: April 1st, 2012 to March 31st, 2017

“Mechanisms of Lung Carcinogenesis Induced by Asbestos and Cigarette Smoke”
Principal Investigator: Debbie Sullivan
Type: R01
Agency:NIH (R01CA132603)
Period: April 1st, 2008 to March 31st, 2013

“Interaction of EBV and HPV in the Development of Cervical Dysplasia in HIV+ Women”
Principal Investigator: Michael Hagensee (LSU)
Type: R01
Agency:NIH (R01CA121979)
Period: April 1st, 2008 – March 31st, 2013